Charles River Laboratories International, Inc. · CRL · Next earnings

Charles River Laboratories International, Inc. reports Wednesday, Nov 4, 2026

CRL reports before market open with consensus EPS at $2.97 and revenue at $960.4M. Last quarter: Charles River raises FY2026 outlook after strong Q3; demand and margins improve

Reports Before market open0 days awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $2.97 Calendar consensus
Consensus revenue $960.4M Calendar consensus
Report date Nov 4, 2026 Wednesday, date estimated
Session Before market open 0 days away

Where CRL left off: FY2026 Q3

Full report

Charles River raises FY2026 outlook after strong Q3; demand and margins improve

EPS surprise — Reported — vs $2.97
Revenue surprise — Reported — vs $960.4M
Stock move -6.0% Event window
Subsequent drift 0.0% Up to 20 sessions

Raised full-year revenue and non-GAAP EPS guidance after Q3 results exceeded prior expectations. The supplied analysis specifies revenue guidance of over 1.5% organic growth; it does not provide the revised EPS range.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • Biotech funding weakness or reduced biopharma R&D spending could weigh on demand.
  • DSA pricing benefits may be delayed, while non-human-primate supply remains constrained, particularly in China.
  • Seasonality, RMS revenue declines and macroeconomic uncertainty could temper growth.

Questions analysts left open

  • When AI-derived molecules will progress to safety assessment and IND stages, and how much current demand reflects AI-related work.
  • When DSA pricing power will translate into revenue and how supply constraints affect margins.
  • Whether seasonal bookings and RMS pricing can offset small-model volume declines.

Ask FN2 about CRL next report

Transcript, numbers and history already loaded
What should I watch for in CRL's next earnings report?How did CRL guide last quarter, and is consensus above or below that?Give me the bull and bear case going into CRL earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Get the CRL recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent CRL quarters

All CRL earnings
-6.0%FY2026 Q3+11.4%FY2026 Q2-0.0%FY2026 Q1-0.3%FY2025 Q4

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q3

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.